Loading clinical trials...
Loading clinical trials...
A Single-Dose, Open-Label, Parallel-Group Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on the Pharmacokinetics of JNJ-53718678
Conditions
Interventions
JNJ-53718678
Locations
2
United States
Orlando Clinical Research Center
Orlando, Florida, United States
The Texas Liver Institute
San Antonio, Texas, United States
Start Date
August 17, 2020
Primary Completion Date
March 16, 2022
Completion Date
March 16, 2022
Last Updated
June 13, 2022
NCT07324616
NCT04271488
NCT06952634
NCT06841315
NCT06619054
NCT06813781
Lead Sponsor
Janssen Research & Development, LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions